ENOV Stock Analysis: Enovis | NYSE
Medical Devices | NYSE, USA | Market Cap: 1.216m USD | 12M Return: -35.1% | US1940145022 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 25.3M
EPS Trend: 95.5%
Qual. Beats: 0
Rev. Trend: 95.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Enovis Corporation (NYSE: ENOV) is a U.S.-based medical technology company headquartered in Wilmington, Delaware, that develops and markets clinical solutions across two business segments: Prevention and Recovery, which supplies orthopedic bracing, hot/cold therapy, bone growth stimulators, vascular and pain management devices, and physical therapy products; and Reconstructive, which provides implants, instrumentation, and enabling technologies for joint replacement, limb reconstruction, and foot, ankle, and extremity procedures. The company sells through independent distributors, direct sales staff, and direct-to-patient channels, serving orthopedic specialists, surgeons, physical therapists, and other healthcare professionals.
Founded in 1995 and formerly known as Colfax Corporation, Enovis operates within the GICS Health Care Equipment sub-industry, a sector characterized by long product development cycles, regulatory approval requirements (such as FDA clearance in the U.S. and CE marking in Europe), and demand tied to aging populations, elective surgical volumes, and musculoskeletal health trends.
- Reconstructive hip and knee implant sales accelerate revenue growth
- Elective surgery volumes drive Reconstructive segment quarterly results
- Capital allocation pivots to orthopedic M&A post-Colfax spin-off
| Net Income: -1.10b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 1.77 > 1.0 |
| NWC/Revenue: 26.24% < 20% (prev 32.53%; Δ -6.28% < -1%) |
| CFO/TA 0.07 > 3% & CFO 270.1m > Net Income -1.10b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.98 > 1.5 & < 3 |
| Outstanding Shares: last quarter (57.6m) vs 12m ago 1.42% < -2% |
| Gross Margin: 57.43% > 18% (prev 57.59%; Δ -0.16% > 0.5%) |
| Asset Turnover: 52.27% > 50% (prev 43.60%; Δ 8.66% > 0%) |
| Interest Coverage Ratio: -18.23 > 6 (EBIT TTM -1.01b / Interest Expense TTM 55.5m) |
| A: 0.16 (Total Current Assets 1.21b - Total Current Liabilities 612.1m) / Total Assets 3.77b |
| B: -0.39 (Retained Earnings -1.48b / Total Assets 3.77b) |
| C: -0.23 (EBIT TTM -1.01b / Avg Total Assets 4.39b) |
| D: 0.65 (Book Value of Equity 1.48b / Total Liabilities 2.29b) |
| Altman-Z'' = -1.10 = CCC |
| DSRI: 0.93 (Receivables 441.8m/453.7m, Revenue 2.30b/2.19b) |
| GMI: 1.00 (GM 57.59% / 57.43%) |
| AQI: 0.81 (AQ_t 0.52 / AQ_t-1 0.64) |
| SGI: 1.05 (Revenue 2.30b / 2.19b) |
| TATA: -0.36 (NI -1.10b - CFO 270.1m) / TA 3.77b) |
| Beneish M = -3.20 (Cap -4..+1) = AA |
As of November 02, 2026, the stock is trading at USD 19.91 with a total of 2,520,335 shares traded. Over the past week, the price has changed by -5.55%, over one month by +7.85%, over three months by -32.05% and over the past year by -35.13%.
Current recommended Stop Loss: 18.40 (which is 7.6% or 1.6 ATR below the current price).
Enovis has received a consensus analysts rating of 4.69. Therefore, it is recommended to buy ENOV.
- StrongBuy: 10
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 36.1 | 81.2% |
P/E Forward = 4.6361
P/S = 0.5293
P/B = 0.7114
P/EG = 1.8989
Revenue TTM = 2.30b USD
EBIT TTM = -1.01b USD
EBITDA TTM = -717.0m USD
Long Term Debt = 1.25b USD (from longTermDebt, last quarter)
Short Term Debt = 62.8m USD (from shortTermDebt, last quarter)
Debt = 1.45b USD (from shortLongTermDebtTotal, last quarter) + Leases 84.5m
Net Debt = 1.44b USD (calculated: Debt 1.45b - CCE 12.6m)
Enterprise Value = 2.66b USD (1.22b + Debt 1.45b - CCE 12.6m)
Interest Coverage Ratio = -18.23 (Ebit TTM -1.01b / Interest Expense TTM 55.5m)
EV/FCF = 41.73x (Enterprise Value 2.66b / FCF TTM 63.7m)
FCF Yield = 2.40% (FCF TTM 63.7m / Enterprise Value 2.66b)
FCF Margin = 2.77% (FCF TTM 63.7m / Revenue TTM 2.30b)
Net Margin = -47.97% (Net Income TTM -1.10b / Revenue TTM 2.30b)
Gross Margin = 57.43% ((Revenue TTM 2.30b - Cost of Revenue TTM 977.6m) / Revenue TTM)
Gross Margin QoQ = 61.64% (prev 54.92%)
Tobins Q-Ratio = 0.71 (Enterprise Value 2.66b / Total Assets 3.77b)
Interest Expense / Debt = 3.82% (Interest Expense 55.5m / Debt 1.45b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -800.1m (EBIT -1.01b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.98 (Total Current Assets 1.21b / Total Current Liabilities 612.1m)
Debt / Equity = 0.98 (Debt 1.45b / totalStockholderEquity, last quarter 1.48b)
Debt / EBITDA = -2.01 (negative EBITDA) (Net Debt 1.44b / EBITDA -717.0m)
Debt / FCF = 22.64 (Net Debt 1.44b / FCF TTM 63.7m)
Total Stockholder Equity = 1.62b (last 4 quarters mean from totalStockholderEquity)
RoA = -25.07% (Net Income -1.10b / Total Assets 3.77b)
RoE = -68.17% (Net Income TTM -1.10b / Total Stockholder Equity 1.62b)
RoCE = -35.37% (EBIT -1.01b / Capital Employed (Equity 1.62b + L.T.Debt 1.25b))
RoIC = -24.97% (negative operating profit) (NOPAT -800.1m / Invested Capital 3.20b)
WACC = 5.78% (E(1.22b)/V(2.67b) * Re(9.08%) + D(1.45b)/V(2.67b) * Rd(3.82%) * (1-Tc(0.21)))
Discount Rate = 9.08% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 65.16 | Cagr: 2.33%
[DCF] Terminal Value 75.44% ; FCFF base≈63.7m ; Y1≈63.9m ; Y5≈67.7m
[DCF] Fair Price = N/A (negative equity: EV 1.05b - Net Debt 1.44b = -387.9m; debt exceeds intrinsic value)
EPS Correlation: 95.52 | EPS CAGR: 17.30% | SUE: -0.82 | # QB: 0
Revenue Correlation: 95.83 | Revenue CAGR: 12.96% | SUE: 0.13 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.77 | Chg30d=-0.89% | Revisions=-40% | Analysts=13
EPS current Year (2026-12-31): EPS=3.63 | Chg30d=-0.34% | Revisions=-40% | GrowthEPS=+9.9% | GrowthRev=+4.0%
EPS next Year (2027-12-31): EPS=3.54 | Chg30d=-4.04% | Revisions=-40% | GrowthEPS=-2.3% | GrowthRev=+4.9%
[Analyst] Revisions Ratio: -67% (up=0, down=6)